Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database

Osteoporosis International

Volumn 24, Issue 1, 2013, Pages 369-372

  Abrahamsen, B ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Bisphosphonates; Databases; Epidemiology; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; DATA BASE; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SAFETY; TREATMENT DURATION;

ADULT; AGE DISTRIBUTION; AGED; BONE DENSITY CONSERVATION AGENTS; DATABASES, FACTUAL; DENMARK; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; SEX DISTRIBUTION; TIME FACTORS;

EID: 84872328770     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-1994-x     Document Type: Article

References (14)

1. Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
2. Rizzoli R, Akesson K, Bouxsein M et al (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporosis Int 22:373-390
3. Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728-1737
4. Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95(4):1555-1655
5. Compston J (2011) Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporosis Int 22:2951-2961
6. Pazianas M, Abrahamsen B (2011) Safety of bisphosphonates. Bone 49(1):103-110
7. Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporosis Int 20:299-307
8. Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022
9. Kothawala P, Badamgarav E, Ryu S et al (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493-1501
10. Brookhart MA, Avorn J, Katz JN et al (2007) Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 120:251-256
11. Cramer JA, Silverman SL, Gold DT (2007) Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin 23:2369-2377
12. Seeman E, Compston J, Adachi J et al (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporosis Int 18:711-719
13. Compston J (2010) Bisphosphonates and atypical femoral fractures: a time for reflection. Maturitas 65:3-4
14. Seeman E (2009) To stop or not to stop, that is the question. Osteoporos Int 20:187-195